Fu H, Mo X, Ivanov A
Nat Rev Cancer. 2025; 25(3):189-208.
PMID: 39810024
DOI: 10.1038/s41568-024-00784-6.
Patil M, Bihari A
Mol Biol Rep. 2024; 52(1):46.
PMID: 39658610
DOI: 10.1007/s11033-024-10051-4.
Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M
Biomark Res. 2024; 12(1):137.
PMID: 39538363
PMC: 11565275.
DOI: 10.1186/s40364-024-00676-9.
Valenti F, Ganci F, Sacconi A, Lo Sardo F, DAndrea M, Sanguineti G
J Mol Med (Berl). 2024; 102(12):1485-1501.
PMID: 39480521
DOI: 10.1007/s00109-024-02499-5.
Tornesello M
Int J Mol Med. 2024; 55(1).
PMID: 39450536
PMC: 11554381.
DOI: 10.3892/ijmm.2024.5448.
The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes.
Borlak J, Ciribilli Y, Bisio A, Selvaraj S, Inga A, Oh J
J Transl Med. 2024; 22(1):845.
PMID: 39285385
PMC: 11403941.
DOI: 10.1186/s12967-024-05623-8.
Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein.
Han I, Thayer K
ACS Omega. 2024; 9(18):19837-19847.
PMID: 38737036
PMC: 11079909.
DOI: 10.1021/acsomega.3c08509.
Activation of p53 signaling and regression of breast and prostate carcinoma cells by spirooxindole-benzimidazole small molecules.
Barakat A, Alshahrani S, Al-Majid A, Alamary A, Haukka M, Abu-Serie M
Front Pharmacol. 2024; 15:1358089.
PMID: 38650632
PMC: 11033320.
DOI: 10.3389/fphar.2024.1358089.
Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O, Baek M, Wooldrik C, Johnson K, Fisher K, Lou J
EMBO J. 2024; 43(9):1740-1769.
PMID: 38565949
PMC: 11066040.
DOI: 10.1038/s44318-024-00085-6.
Regulatory RNAs in immunosenescence.
Talepoor A, Doroudchi M
Immun Inflamm Dis. 2024; 12(3):e1209.
PMID: 38456619
PMC: 10921898.
DOI: 10.1002/iid3.1209.
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B, Yang P, Zhang S
Cancer Commun (Lond). 2024; 44(3):297-360.
PMID: 38311377
PMC: 10958678.
DOI: 10.1002/cac2.12520.
Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence.
cizmarikova M, Michalkova R, Mirossay L, Mojzisova G, Zigova M, Bardelcikova A
Biomolecules. 2023; 13(11).
PMID: 38002335
PMC: 10669545.
DOI: 10.3390/biom13111653.
CKAP4 and mutant p53 cooperatively abrogate cell cycle checkpoint to induce genotoxic resistance in ovarian cancer.
Huang C, Zhao W, Hao Q, Chen J, Wu L, Yang W
Clin Transl Med. 2023; 13(11):e1476.
PMID: 37983936
PMC: 10659766.
DOI: 10.1002/ctm2.1476.
Transcription factor NFYa controls cardiomyocyte metabolism and proliferation during mouse fetal heart development.
Cui M, Bezprozvannaya S, Hao T, Elnwasany A, Szweda L, Liu N
Dev Cell. 2023; 58(24):2867-2880.e7.
PMID: 37972593
PMC: 11000264.
DOI: 10.1016/j.devcel.2023.10.012.
Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment.
Dong X, Li C, Deng C, Liu J, Li D, Zhou T
Oncogene. 2023; 43(2):92-105.
PMID: 37952080
PMC: 10774126.
DOI: 10.1038/s41388-023-02886-1.
Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
Li M, Sun D, Song N, Chen X, Zhang X, Zheng W
Oncol Rep. 2023; 50(3).
PMID: 37449494
PMC: 10394732.
DOI: 10.3892/or.2023.8599.
E2F7 drives autotaxin/Enpp2 transcription via chromosome looping: Repression by p53 in murine but not in human carcinomas.
Lin K, Lee S, Dacheux M, Norman D, Balogh A, Bavaria M
FASEB J. 2023; 37(7):e23058.
PMID: 37358838
PMC: 10364077.
DOI: 10.1096/fj.202300838R.
The crosstalk between ubiquitin-conjugating enzyme E2Q1 and p53 in colorectal cancer: An in vitro analysis.
Rasouli M, Khakshournia S, Vakili O, Dastghaib S, Seghatoleslam A, Shafiee S
Med Oncol. 2023; 40(7):199.
PMID: 37294480
DOI: 10.1007/s12032-023-02039-0.
Role of p53 in breast cancer progression: An insight into p53 targeted therapy.
Marvalim C, Datta A, Lee S
Theranostics. 2023; 13(4):1421-1442.
PMID: 36923534
PMC: 10008729.
DOI: 10.7150/thno.81847.
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X
Cell Death Dis. 2022; 13(11):974.
PMID: 36400749
PMC: 9674619.
DOI: 10.1038/s41419-022-05408-1.